The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg
bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by
0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS)
as compared with placebo in acute ischemic stroke (AIS) patients treated with standard of
care thrombolysis (0.9mg/kg IV rt-PA or 0.25mg/kg IV tenecteplase or TNK) within three hours
of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care.
Time of onset is defined as the last time the patient was last known to be well.
Phase:
Phase 3
Details
Lead Sponsor:
University of Cincinnati Washington University School of Medicine
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)